Hagens Berman Launches Investigation Into CVRx Following 59% Stock Plunge
A 59% collapse in CVRx Inc. stock has triggered a formal investigation by Hagens Berman, a national shareholder rights firm. The probe focuses on potential federal securities law violations following a series of disclosures involving a Department of Justice inquiry, executive turnover, and a sudden breakdown in critical reimbursement approvals.
The investigation centers on whether CVRx misled investors about the stability of its sales force and the viability of its commercial strategy for Barostim, its flagship heart failure device. While the company previously touted a $10.5 billion market opportunity and a near-complete sales transformation, recent regulatory and operational hurdles have painted a different picture. On May 14, 2026, the company received a Civil Investigative Demand from the Department of Justice, raising questions about potential improper marketing and kickbacks to healthcare providers.
Operational instability compounded these legal pressures. CVRx revealed that approval rates from its primary Medicare Advantage payer plummeted from 80% to just 25%, while revenue guidance was slashed amid widespread sales force turnover. Shortly after the market reacted to these disclosures on August 7, 2026, the company abruptly fired Chief Revenue Officer Robert John. Reed Kathrein, the Hagens Berman partner leading the case, stated that the firm is now examining whether the DOJ inquiry and the executive's termination are directly linked to previously undisclosed internal failures.
Comments (0)
No comments yet. Be the first!